David Porter

7PUBLICATIONS
19CO-AUTHORS
Nutritional epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Neural engineeringMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 18, 2025
A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity.

Nuala Helsby, Katrina Sharples, Yu Jin Kim

|Jan 25, 2024
Liposome-enabled bufalin and doxorubicin combination therapy for trastuzumab-resistant breast cancer with a focus on cancer stem cells.

Yu Gao, Andrew N Shelling, Emma Nolan

|Mar 13, 2023
Stability of trastuzumab during nanomedicine formulation using SEC-HPLC coupled with polyacrylamide gel electrophoresis.

Yu Gao, Andrew N Shelling, David Porter

|Sep 27, 2021
Severe 5-Fluorouracil-Associated Gastrointestinal Toxicity Unexplained by Dihydropyrimidine Dehydrogenase Deficiency and Renal Impairment: Should We Be Investigating Other Elimination Pathways to Assess the Risk of 5-Fluorouracil Toxicity?

Soo Hee Jeong, Ottiniel Chavani, Kathryn Burns

|Jun 11, 2021
Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.

Nuala Helsby, Minghan Yong, Kathryn Burns

|Mar 09, 2021
Comparison of a thymine challenge test and endogenous uracil-dihydrouracil levels for assessment of fluoropyrimidine toxicity risk.

Kathryn E Burns, Ottiniel Chavani, Soo Hee Jeong

Pageof 2

Frequent Collaborators

5 joint publications

Kathryn E Burns

5 joint publications

Michael P Findlay

5 joint publications

Nuala Helsby

3 joint publications

Soo Hee Jeong